APNAR Pharma Acquires New Jersey-Based Aurex Laboratories With US FDA-Approved Finished Dosing Capabilities, Expanding Its Global Footprint
EAST WINDSOR, NJ, February 3, 2022 /PRNewswire/ — APNAR Pharma LP (APNAR) headquartered in Chino, California acquired East Windsor, New Jersey based at Aurex Laboratories (Aurex) for an undisclosed fee. This acquisition enhances APNAR’s capabilities, scale and global footprint and expands APNAR’s pipeline.
Dharmesh Patelthe President of APNAR said: “As part of our well-defined strategy and our commitment to have manufacturing in The United States of America, we are delighted to acquire Aurex. This step will position APNAR as a company with a global footprint in the United States and India.”
Sanjay BhargavCOO of APNAR added, “In addition to adding state-of-the-art facilities to APNAR’s capabilities in the United States, we are thrilled to welcome to APNAR an incredible, experienced, highly skilled and dedicated team of scientists , manufacturers, regulatory and project management personnel.”
“In addition to developing and manufacturing APNAR’s own products, we look forward to working collaboratively with other companies for outsourcing, co-development and contract manufacturing,” Patel added.
“We look forward to manufacturing APNAR’s 5 ANDAs and other drugs in the United States to ensure supply chain safety and excellence,” Bhargav added.
Nailesh Bhat acted as strategic advisor for Aurex Laboratories and APNAR Pharma.
About APNAR Pharma LP
Based at Chino, California, APNAR Pharma is a rapidly growing private pharmaceutical company. We develop, manufacture, package, sell, market and distribute generic and OTC pharmaceutical products. APNAR has R&D and manufacturing facilities in East Windsor, New Jersey, United States and Gavasad, Gujarat, India.